Search details
1.
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Cell
; 173(2): 321-337.e10, 2018 04 05.
Article
in English
| MEDLINE | ID: mdl-29625050
2.
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
EMBO J
; 39(21): e105111, 2020 11 02.
Article
in English
| MEDLINE | ID: mdl-32945574
3.
Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.
Br J Dermatol
; 190(4): 549-558, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-38006317
4.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin
; 67(6): 472-492, 2017 Nov.
Article
in English
| MEDLINE | ID: mdl-29028110
5.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36460017
6.
Designing a wholly online, multidisciplinary Master of Cancer Sciences degree.
BMC Med Educ
; 23(1): 544, 2023 Jul 31.
Article
in English
| MEDLINE | ID: mdl-37525150
7.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 381(16): 1535-1546, 2019 10 17.
Article
in English
| MEDLINE | ID: mdl-31562797
8.
Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
Curr Oncol Rep
; 24(8): 1071-1079, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35366166
9.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Proc Natl Acad Sci U S A
; 116(36): 17990-18000, 2019 09 03.
Article
in English
| MEDLINE | ID: mdl-31439820
10.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Article
in English
| MEDLINE | ID: mdl-32534646
11.
Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
Int J Cancer
; 147(8): 2176-2189, 2020 10 15.
Article
in English
| MEDLINE | ID: mdl-32249419
12.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 377(14): 1345-1356, 2017 10 05.
Article
in English
| MEDLINE | ID: mdl-28889792
13.
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
J Transl Med
; 18(1): 294, 2020 08 03.
Article
in English
| MEDLINE | ID: mdl-32746839
14.
Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic.
Intern Med J
; 50(10): 1282-1285, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32951279
15.
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Br J Cancer
; 121(7): 522-528, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31417188
16.
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Blood
; 129(21): 2882-2895, 2017 05 25.
Article
in English
| MEDLINE | ID: mdl-28283481
17.
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Lancet Oncol
; 19(5): 672-681, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29602646
18.
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Int J Cancer
; 142(10): 2139-2152, 2018 05 15.
Article
in English
| MEDLINE | ID: mdl-29243224
19.
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
Br J Cancer
; 118(10): 1289-1295, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29755118
20.
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Br J Cancer
; 118(6): 777-784, 2018 03 20.
Article
in English
| MEDLINE | ID: mdl-29438370